Precision BioSciences Inc. has outlined its strategic priorities through 2026, focusing on the continued advancement of its clinical-stage gene editing programs. The company plans to progress its PBGENE-HBV candidate for chronic hepatitis B through the ongoing Phase 1/2a ELIMINATE-B dose-finding study, with efforts aimed at optimizing dosing regimens and preparing for the study’s expansion phase. Precision BioSciences also intends to initiate clinical evaluation of PBGENE-DMD for Duchenne muscular dystrophy in early 2026, as part of the Phase 1/2 FUNCTION-DMD trial. The company expects its current cash position, along with anticipated additional funding sources, to support operations through 2028. Further clinical and regulatory milestones are anticipated, with additional program updates planned for hepatitis-focused medical conferences in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112331937) on January 12, 2026, and is solely responsible for the information contained therein.